Opportunities for increasing effectiveness of pharmacotherapy of acute respiratory viral infections in children

Authors

  • O.Ya. Mishchenko Institute for Advanced Training of Pharmacy Specialists of the National University of Pharmacy, Ukraine

Keywords:

acute respiratory viral infections, children, treatment, drug based on linden extract

Abstract

Acute respiratory viral infections (ARVI) occupy a leading place in the structure of childhood morbidity. ARVIs are characterized by the speed and ease of transmission of pathogens, high contagiousness and variability, which makes their treatment one of the complex clinical tasks. Medical and social significance of acute respiratory viral infections is associated with the development of serious complications and significant treatment costs. Medicines for ARVIs treatment should have the ability to eliminate the pathogen, stimulate body's resistance, correct functional disorders occurring against the background of the disease, have anti-inflammatory and detoxification effects, as well as a good safety profile. The drug Malipin based on linden extract meets these requirements. Proven clinical efficacy, good safety profile, pleasant organoleptic characteristics, and age range for prescription allow to recommend it for the complex treatment of ARVIs in children from one year of age, including those with recurrent respiratory diseases, in order to increase the effectiveness of etiopathogenetic therapy.

References

Gliadelova NP, Kozachuk VG. (2020). Phytotherapeutic medicines in the treatment of acute respiratory infections in children. Modern pediatrics.Ukraine. 1(105): 82—88. doi 10.15574/SP.2020.105.82

Erofeyeva MK, Pozdnyakova MG, Maksakova VL. (2011). Aktualnyye voprosy profilaktiki grippa i drugikh ORVI. RMZh. 32(19): 2091—2096.

Instruktsiia do zastosuvannia preparatu malipin. https://compendium.com.ua/dec/265568/

Kazyukova TV i dr. (2011). Semeynaya profilaktika grippa i ostrykh respiratornykh infektsiy v period podyema sezonnoy zabolevayemosti. RMZh. 2(19): 118—123.

Karetkina GN. (2009). Primeneniye induktorov interferona dlya lecheniya i profilaktiki grippa i drugikh ORVI. Lechashchiy vrach. 9. http://www.lvrach.ru/2009/10/10861672/

Kiselev OI, Romantsov MG, Sologub TV. (2011). Etiopatogeneticheskaya farmakoterapiya ORVI i grippa. Lechashchiy vrach. 2: 92—96.

Markova TP. (2010). Profilaktika i lecheniye respiratornykh infektsiy. RMZh. 2(18): 77—81.

MOZ Ukrainy. (2014). Pro zatverdzhennia ta vprovadzhennia medyko tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry hrypi ta hostrykh respiratornykh infektsiiakh. Nakaz MOZ Ukrainy vid 16.07.2014 N499. http://www.dec.gov.ua/

Mustafayev DM. (2013). Aktualnyye voprosy lecheniya ostrykh respiratornykh virusnykh infektsiy. Klinitsist. 3—4: 109—116.

Nisevich LL, Volkov KS, Alekseyeva AA i dr. (2015). Podkhody k terapii ostrykh respiratornykh infektsiy i grippa pri sezonnom uvelichenii zabolevayemosti. Voprosy sovremennoy pediatrii. 14(1): 64—69.

Pechinka AM, Dzeman MI. (2010). Hostri respiratorni zakhvoriuvannia: pytannia klinichnoi diahnostyky ta likuvannia (lektsiia). Ukr med chasopys. 5(79): 94—103.

Randomizirovannoye, otkrytoye issledovaniye po izucheniyu effektivnosti i perenosimosti lekarstvennogo sredstva MALIPIN (LIPOMAL). sirop (OOO Aflofarm Farmatsiya Polska. Polsha) v kompleksnom lechenii patsiyentov v vozraste ot 1 do 6 let s ostrymi respiratornymi virusnymi infektsiyami v sravnenii s gruppoy patsiyentov. poluchayushchikh tolko bazisnuyu terapiyu. Klinicheskiy otchet FFAP/MAL/01 Malipin.

Romantsov MG, Ershov FI. (2007). Sovremennyy vzglyad na lecheniye i profilaktiku grippa i ostroy respiratornoy virusnoy infektsii. Spravochnik poliklinicheskogo vracha 11: 14—16.

Sadovnikova II. (2011). Sezonnyye nepriyatnosti i puti ikh preodoleniya. RMZh.31(19): 1954—1958.

Uchaykin VF. (2001). Diagnostika. lecheniye i profilaktika grippa i ostrykh respiratornykh zabolevaniy u detey. Posobiye dlya vrachey. Moskva: 16.

Published

2020-03-28